Xcout IntelACRUX LIMITED
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Subscribe to see ACRUX LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ACRUX LIMITED at a glance
ACRUX LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in West Melbourne, Australia. Xcout tracks 16 named people at ACRUX LIMITED, including John Warmbrunn (Managing Director & Chief Executive Officer).
ACRUX LIMITED leadership
- John WarmbrunnManaging Director & Chief Executive Officer
- Mark Steven FogelPresident, Chief Executive Officer & Director
- Kyle K. BrengelChief Operating Officer
- Eldron C. BlackwellChief Financial Officer & Senior Vice President
- Jaclyn Alyce JesbergerChief Legal Officer, Senior Vice President & Secretary
- Linda KilpatrickVice President, Chief Accounting Officer & Controller
10 more named people on record for ACRUX LIMITED, with roles, board committees and tenure — see the full roster →
ACRUX LIMITED competitors
A few of ACRUX LIMITED's closest competitors — see the full list of competitors and alternatives →
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Marius Pharmaceuticals, LLC develops hormone health therapies focused on testosterone deficiency and metabolic vitality. The company offers KYZATREX, an oral prescription drug used to treat adult men with low or no testosterone levels due to specific medical conditions.
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.
AFT Pharmaceuticals Limited engages in the complete lifecycle of pharmaceutical products, from their initial development and licensing to their distribution and ultimate sale. The company's reach extends throughout New Zealand, Australia, Asia, and various other international markets. Its extensive product range encompasses treatments for allergies, cold and flu symptoms, ophthalmic conditions, first aid, pain management, digestive health, dermatological concerns, and medicated vitamin supplements. Established in 1997, AFT Pharmaceuticals has its corporate headquarters situated in Auckland, New Zealand.
Get ACRUX LIMITED's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ACRUX LIMITED in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access